What is ALT's market cap?

$412.38M, based on the Nov 4 close of $2.12.

Does Altimmune pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ALT is sold short?

42.2M shares, 22.2% of float, as of Oct 15, 2026.

What sector is ALT in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · ALTHealthcarePharmaceuticals

Altimmune, Inc. Common Stock (ALT)

$2.12+3.92%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$2.04▼ 48.48% in range

Nov 3, 2025Low $2.02 · High $6.18Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

Altimmune closed at $2.12 on Nov 4, up 3.92%, 65.7% below its 52-week closing high. Volume of 3.5M shares was 1.01× its 20-day average (close to normal).

Split-adjusted performance: -20.6% over one month, -35.0% over six months, -46.5% over one year.

Short interest was 42.2M shares at the Oct 15 settlement, down 8.3% from the prior report (22.2% of float, 10.4 days to cover).

Market cap$412.4M194.5M shares

Revenue · quarter$0.00−100.0% YoY

Diluted EPS$-0.12—

P/E · TTM—P/S 13,302.5×

Net margin—

Dividend yieldNone

52-week range2.02 – 6.18−65.7% from high

Volume3.5M1.01× 20-day avg

Volatility · 60d47.8%Annualised

Short % of float22.2%10.4 days to cover

Net cash$291.5MCash $326.3M

Next earnings—Not scheduled

Split-adjusted performance

1W +1.0%1M −20.6%3M −29.6%6M −35.0%YTD −41.3%1Y −46.5%3Y −11.3%5Y −80.7%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum38

Revenue growth1

Net margin—

Value (low P/E)—

Size58

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short42.2M−8.3% vs prior

Days to cover10.4Settled Oct 15

% of float22.2%

Short vol. 10d50.7%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ALTAltimmune	$2.12	+3.92%	−35.0%	−100.0%	—	—	$412.4M
ASMBAssembly Biosciences	$19.87	−0.25%	−36.6%	+38.9%	−28.8%	—	$404.6M	Compare
PRTAProthena	$8.39	+2.19%	−25.0%	−77.1%	−1839.9%	—	$430.7M	Compare
BLSMBlossomHill Therapeutics	$12.38	−0.24%	—	—	—	—	$393.5M	Compare
TLRYTilray Brands	$2.96	+11.70%	−48.6%	+22.7%	−16.8%	—	$437.5M	Compare
INDPIndaptus Therapeutics	$3.30	+1.85%	+61.0%	—	—	—	$439.7M	Compare
CRMDCorMedix	$5.66	+1.80%	−29.7%	+156.5%	25.5%	2.4	$441.2M	Compare
RZLTRezolute, Inc. Common Stock (NV)	$3.96	−1.25%	+26.1%	—	—	—	$383.0M	Compare
RLMDRelmada Therapeutics	$4.17	−2.34%	−46.9%	—	—	—	$444.8M	Compare

News about Altimmune

All news →

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?Zacks Investment Research · Sep 11, 2026▲ Positive Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026GlobeNewswire Inc. · May 28, 2026▲ Positive Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of SecuritiesBenzinga · Apr 27, 2026▲ Positive Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of SecuritiesGlobeNewswire Inc. · Apr 23, 2026▲ Positive

Quick answers

What does Altimmune do?: Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD).
What is ALT's market cap?: $412.38M, based on the Nov 4 close of $2.12.
Does Altimmune pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ALT is sold short?: 42.2M shares, 22.2% of float, as of Oct 15, 2026.
What sector is ALT in?: Healthcare, in the Pharmaceuticals industry.

About Altimmune

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

HQ: Gaithersburg, MD57 employeesListed Oct 6, 2005altimmune.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology